Search Results - "Liu, G Frank"

Dynamic RMST curves for survival analysis in clinical trials by Liao, Jason J Z, Liu, G Frank, Wu, Wen-Chi

“…The data from immuno-oncology (IO) therapy trials often show delayed effects, cure rate, crossing hazards, or some mixture of these phenomena. Thus, the…”
Get full text

Postdose 3 G1 serum neutralizing antibody as correlate of protection for pentavalent rotavirus vaccine by Liu, G. Frank, Hille, Darcy, Kaplan, Susan S., Goveia, Michelle G.

“…Although clinical trials of the pentavalent rotavirus vaccine (RotaTeq®, RV5) have demonstrated efficacy against RV gastroenteritis (RGE) in low and…”
Get full text

Comparisons of Methods for Analysis of Repeated Binary Responses with Missing Data by Frank Liu, G., Zhan, Xiaojiang

“…It is important yet challenging to choose an appropriate analysis method for the analysis of repeated binary responses with missing data. The conventional…”
Get full text

A dynamic power prior for borrowing historical data in noninferiority trials with binary endpoint by Liu, G. Frank

“…Summary Traditionally, noninferiority hypotheses have been tested using a frequentist method with a fixed margin. Given that information for the control group…”
Get full text

On analysis of longitudinal clinical trials with missing data using reference-based imputation by Liu, G. Frank, Pang, Lei

“…Reference-based imputation (RBI) methods have been proposed as sensitivity analyses for longitudinal clinical trials with missing data. The RBI methods…”
Get full text

Heterogeneity of Rotavirus Vaccine Efficacy Among Infants in Developing Countries by Gruber, Joann F, Hille, Darcy A, Liu, G Frank, Kaplan, Susan S, Nelson, Micki, Goveia, Michelle G, Mast, T Christopher

“…BACKGROUND:Rotavirus is the leading cause of severe diarrhea worldwide in young children. Although rotavirus vaccine efficacy is high in developed countries,…”
Get full text

Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine by Xu, Jin, Stek, Jon E, Ziani, Eddy, Liu, G Frank, Lee, Andrew W

“…DTaP5-HB-IPV-Hib is a fully liquid, hexavalent vaccine containing a 5-antigen pertussis component, approved since 2016 in Europe [Vaxelis; DTaP5-HB-IPV-Hib…”
Get full text

Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine by Xu, Jin, Stek, Jon E, Ziani, Eddy, Liu, G Frank, Lee, Andrew W

“…BACKGROUND:DTaP5-HB-IPV-Hib is a fully liquid, hexavalent vaccine containing a 5-antigen pertussis component, approved since 2016 in Europe [Vaxelis;…”
Get full text

A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11–12 months by Silfverdal, Sven-Arne, Icardi, Giancarlo, Vesikari, Timo, Flores, Sheryl A, Pagnoni, Marco F, Xu, Jin, Liu, G. Frank, Stek, Jon E, Boisnard, Florence, Thomas, Stéphane, Ziani, Eddy, Lee, Andrew W

“…Abstract Background Combination vaccines simplify vaccination visits and improve coverage and timeliness. DTaP5-HB-IPV-Hib is a new investigational,…”
Get full text

A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months by Vesikari, Timo, Becker, Thomas, Vertruyen, Andre F, Poschet, Katleen, Flores, Sheryl A, Pagnoni, Marco F, Xu, Jin, Liu, G Frank, Stek, Jon E, Boisnard, Florence, Thomas, Stéphane, Ziani, Eddy, Lee, Andrew W

“…BACKGROUND:Combination vaccines simplify vaccination visits and improve coverage and timeliness. Diphtheria–tetanus toxoids–acellular pertussis 5, hepatitis B,…”
Get full text

Evaluation of program success for programs with multiple trials in binary outcomes by Wang, Meihua, Liu, G. Frank, Schindler, Jerald

“…A late‐stage clinical development program typically contains multiple trials. Conventionally, the program's success or failure may not be known until the…”
Get full text

Evaluating the adaptive performance of flexible sample size designs with treatment difference in an interval by Liu, G. Frank, Zhu, G. Ray, Cui, Lu

“…In clinical trials, the study sample size is often chosen to provide specific power at a single point of a treatment difference. When this treatment difference…”
Get full text

Confidence intervals for an exposure adjusted incidence rate difference with applications to clinical trials by Liu, G. Frank, Wang, Junyuan, Liu, Kenneth, Snavely, Duane B.

“…To summarize safety data such as clinical adverse experiences in clinical trials with a moderate to long‐term follow‐up, we may use a measurement which…”
Get full text

Testing for Crossover of Two Hazard Functions Using Gail and Simon's Method by Chen, Y. H. Joshua, Liu, G. H. Frank

“…Crossover of two hazard functions is sometimes called qualitative nonproportionality where the hazard ratio could be >1 in some time intervals but <1 in some…”
Get full text

A Note on the Estimate of Treatment Effect from a Cox Regression Model When the Proportionality Assumption Is Violated by Joshua Chen, Y. H., Frank Liu, G. H.

“…Cox proportional hazards regression model has been widely used to estimate the effect of a prognostic factor on a time-to-event outcome. In a survey of…”
Get full text

For the Special Issue on Statistical Methods for Clinical Trials and Precision Medicine

Get full text

Noninferiority Testing in Clinical Trials: Issues and Challenges by Liu, G. Frank

Get full text